Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 4:9:1117323.
doi: 10.3389/fmolb.2022.1117323. eCollection 2022.

Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers

Nicola Fusco  1   2 , Umberto Malapelle  3 , Carmen Criscitiello  1   4
Affiliations
Editorial

Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers

Nicola Fusco et al. Front Mol Biosci. .
No abstract available

Keywords: biomarkers; breast cancer; editorial; precision medicine; predictive pathology.

PubMed Disclaimer

Conflict of interest statement

NF has received honoraria for consulting, advisory role, speaker bureau, travel, and/or research grants from Merck Sharp and Dohme (MSD), Boehringer Ingelheim, Novartis, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline (GSK), Gilead, Diaceutics, Adicet Bio, and Sermonix. UM has received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientifics, Eli Lilly, Diaceutics, GSK, Merck and AstraZeneca, Janssen, Diatech, Novartis, and Hedera. CC reports personal fees for consulting, advisory role and speakers’ bureau from Roche, Novartis, Pfizer, Lilly, MSD, AstraZeneca, Gilead, Seagen, and Daiichi Sankyo. These companies had no role in the design of the study; in the Research Topic, analyses, or interpretation of data; in the writing of the manuscript, and/or in this editorial activity.

Comment on

  • Editorial on the Research Topic Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers

References

    1. Criscitiello C., Guerini-Rocco E., Viale G., Fumagalli C., Sajjadi E., Venetis K., et al. (2022). Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology. Anticancer Agents Med. Chem. 22 (4), 787–800. 10.2174/1871520621666210706144112 - DOI - PubMed
    1. Dileep G., Gianchandani Gyani S. G. (2022). Artificial intelligence in breast cancer screening and diagnosis. Cureus 14 (10), e30318. 10.7759/cureus.30318 - DOI - PMC - PubMed
    1. Fusco N., Malapelle U., Fassan M., Marchiò C., Buglioni S., Zupo S., et al. (2021). PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer. Front. Oncol. 11, 644737. 10.3389/fonc.2021.644737 - DOI - PMC - PubMed
    1. Fusco N., Ragazzi M., Sajjadi E., Venetis K., Piciotti R., Morganti S., et al. (2021). Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. Histol. Histopathol. 36, 1235–1245. 10.14670/hh-18-376 - DOI - PubMed
    1. Henry N. L., Somerfield M. R., Dayao Z., Elias A., Kalinsky K., McShane L. M., et al. (2022). Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J. Clin. Oncol. 022 (0), 3205–3221. 10.1200/jco.22.01063 - DOI - PubMed

Publication types